Shurui Wang1, Ting Yang1, Aomei Shen2, Wanmin Qiang3, Zihan Zhao2, Fangyuan Zhang2. 1. Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China. 2. Nursing Department, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 3. Nursing Department, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. wanminqiang2020@163.com.
Abstract
PURPOSE: To systematically assess the efficacy and side effects of scalp cooling in patients with breast cancer. METHODS: A systematic literature search was conducted in October 2020 across Cochrane Library, PubMed, Embase, CINAHL, Web of Science, Scopus, and four Chinese databases (CNKI, Wanfang, SinoMed, and VIP database). Our review included all randomized controlled trials, cohort studies, and cross-sectional studies. Two authors independently searched databases, screened studies, extracted data, and evaluated each included study's methodological quality and risk bias. Meta-analysis was performed using Stata 15.1 software package and Revman 5.3 software, with estimates of scalp cooling effect and its side effects from pooled using a random-effects model. This study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO, CRD42020216224). RESULTS: In total, 755 articles were screened and data from 27 studies involving 2202 participants were used in the meta-analysis. Studies meeting inclusion and exclusion criteria were three randomized clinical trials, 12 cohort studies, and 12 cross-sectional studies. The effectiveness rate of using a scalp cooling device to protect hair was 61% (95% CI: 55 to 67%, I2 = 88%, P = 0.000). However, scalp cooling therapy's side effects are not be ignored, such as headache, dizziness, scalp pain, neck pain, feeling cold, heaviness of the head, skin rash, nausea, and overtightened strap. CONCLUSIONS: This review shows that scalp cooling devices can significantly improve the patients with breast cancer chemotherapy-induced alopecia, but the implications of its side effects provide guide for the implementation of this technology.
PURPOSE: To systematically assess the efficacy and side effects of scalp cooling in patients with breast cancer. METHODS: A systematic literature search was conducted in October 2020 across Cochrane Library, PubMed, Embase, CINAHL, Web of Science, Scopus, and four Chinese databases (CNKI, Wanfang, SinoMed, and VIP database). Our review included all randomized controlled trials, cohort studies, and cross-sectional studies. Two authors independently searched databases, screened studies, extracted data, and evaluated each included study's methodological quality and risk bias. Meta-analysis was performed using Stata 15.1 software package and Revman 5.3 software, with estimates of scalp cooling effect and its side effects from pooled using a random-effects model. This study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO, CRD42020216224). RESULTS: In total, 755 articles were screened and data from 27 studies involving 2202 participants were used in the meta-analysis. Studies meeting inclusion and exclusion criteria were three randomized clinical trials, 12 cohort studies, and 12 cross-sectional studies. The effectiveness rate of using a scalp cooling device to protect hair was 61% (95% CI: 55 to 67%, I2 = 88%, P = 0.000). However, scalp cooling therapy's side effects are not be ignored, such as headache, dizziness, scalp pain, neck pain, feeling cold, heaviness of the head, skin rash, nausea, and overtightened strap. CONCLUSIONS: This review shows that scalp cooling devices can significantly improve the patients with breast cancer chemotherapy-induced alopecia, but the implications of its side effects provide guide for the implementation of this technology.
Entities:
Keywords:
Adverse effects; Breast neoplasm; Chemotherapy-induced alopecia; Meta-analysis; Scalp cooling
Authors: Corina J van den Hurk; Mijke Peerbooms; Lonneke V van de Poll-Franse; Johan W Nortier; Jan Willem W Coebergh; Wim P Breed Journal: Acta Oncol Date: 2012-02-06 Impact factor: 4.089
Authors: Hope S Rugo; Paula Klein; Susan Anitra Melin; Sara A Hurvitz; Michelle E Melisko; Anne Moore; Glen Park; Jules Mitchel; Erika Bågeman; Ralph B D'Agostino; Elizabeth S Ver Hoeve; Laura Esserman; Tessa Cigler Journal: JAMA Date: 2017-02-14 Impact factor: 56.272
Authors: Manon M C Komen; Corina J G van den Hurk; Johan W R Nortier; Tjeerd van der Ploeg; P Nieboer; Jacobus J M van der Hoeven; Carolien H Smorenburg Journal: Support Care Cancer Date: 2018-09-11 Impact factor: 3.603
Authors: Paul J Hesketh; Diane Batchelor; Mitch Golant; Gary H Lyman; Nelson Rhodes; Denise Yardley Journal: Support Care Cancer Date: 2004-06-19 Impact factor: 3.603
Authors: V V Shah; T C Wikramanayake; G M DelCanto; C van den Hurk; S Wu; M E Lacouture; J J Jimenez Journal: J Eur Acad Dermatol Venereol Date: 2017-11-24 Impact factor: 6.166
Authors: G Macquart-Moulin; P Viens; M L Bouscary; D Genre; M Resbeut; G Gravis; J Camerlo; D Maraninchi; J P Moatti Journal: Br J Cancer Date: 1997 Impact factor: 7.640